Citadel Advisors
CTMX icon

Citadel Advisors’s CytomX Therapeutics CTMX Stock Holding History

Citadel Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491K Sell
131,000
-5,600
-4% -$21.4K ﹤0.01% 9912
2026
Q1 		$642K Buy
136,600
+57,300
+72% +$291K ﹤0.01% 8683
2025
Q4 		$338K Sell
79,300
-55,200
-41% -$210K ﹤0.01% 9885
2025
Q3 		$429K Sell
134,500
-15,300
-10% -$34.5K ﹤0.01% 9507
2025
Q2 		$340K Buy
149,800
+140,900
+1,583% +$227K ﹤0.01% 9518
2025
Q1 		$5.66K Buy
8,900
+5,200
+141% +$4.03K ﹤0.01% 13802
2024
Q4 		$3.81K Buy
3,700
+700
+23% +$753 ﹤0.01% 13970
2024
Q3 		$3.54K Sell
3,000
-2,500
-45% -$3.18K ﹤0.01% 13646
2024
Q2 		$6.71K Sell
5,500
-3,400
-38% -$6.77K ﹤0.01% 13310
2024
Q1 		$19.4K Sell
8,900
-10,600
-54% -$19.6K ﹤0.01% 13035
2023
Q4 		$30.2K Sell
19,500
-15,000
-43% -$19.7K ﹤0.01% 12260
2023
Q3 		$44.5K Sell
34,500
-600
-2% -$945 ﹤0.01% 11888
2023
Q2 		$60.4K Buy
35,100
+20,500
+140% +$34K ﹤0.01% 11581
2023
Q1 		$22K Sell
14,600
-3,200
-18% -$7.23K ﹤0.01% 13001
2022
Q4 		$28.5K Buy
17,800
+2,500
+16% +$3.7K ﹤0.01% 12800
2022
Q3 		$22K Buy
15,300
+600
+4% +$923 ﹤0.01% 12033
2022
Q2 		$27K Sell
14,700
-1,900
-11% -$3.64K ﹤0.01% 12275
2022
Q1 		$44K Sell
16,600
-18,700
-53% -$71.8K ﹤0.01% 12879
2021
Q4 		$153K Buy
+35,300
New +$207K ﹤0.01% 12224
2021
Q2 		– Sell
-16,300
Closed -$126K – 13759
2021
Q1 		$126K Buy
+16,300
New +$129K ﹤0.01% 12242

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Citadel Advisors's CTMX Position: Q2 2026 in Review

Citadel Advisors reduced its CytomX Therapeutics (CTMX) stake by 42% in Q2 2026, selling an estimated $8.77M and leaving 3,110,509 shares worth $11.7M. The position accounts for ﹤0.01% of the portfolio, ranked #3330.

Citadel Advisors first reported a position in CTMX in Q1 2017 and has held it in 33 quarters since. The position peaked at $25.4M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Citadel Advisors held 3,110,509 shares of CytomX Therapeutics worth $11.7M as of Q2 2026.
  • Citadel Advisors sold 2,295,684 CytomX Therapeutics shares in Q2 2026, an estimated $8.77M.
  • CytomX Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3330 holding.
  • Citadel Advisors first reported a position in CytomX Therapeutics in Q1 2017 and has held it in 33 quarters since.
  • Citadel Advisors's CytomX Therapeutics position peaked at $25.4M in Q1 2026.
  • 178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.